Share on StockTwits

Sunesis Pharmaceuticals (NASDAQ:SNSS) CMO Adam R. Craig sold 2,554 shares of the company’s stock on the open market in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $8.00, for a total transaction of $20,432.00. Following the completion of the sale, the chief marketing officer now directly owns 12,723 shares of the company’s stock, valued at approximately $101,784. The sale was disclosed in a document filed with the SEC, which is available at this link.

Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 3.73% on Friday, hitting $7.49. The stock had a trading volume of 1,903,154 shares. Sunesis Pharmaceuticals has a 1-year low of $3.84 and a 1-year high of $8.46. The stock’s 50-day moving average is $6.72 and its 200-day moving average is $6.07. The company’s market cap is $452.7 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Tuesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

Receive News & Ratings for Sunesis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.